Sign in
Taking peoplePhase 4

Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation

Key facts

Who runs it
Ottawa Heart Institute Research Corporation
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
150 people, planned
Started
30 Apr 2025
Expected to end
30 Oct 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Nicotine Replacement Therapy (Nicotine patch plus NRT gum or lozenge)
  • Cytisine
  • Varenicline (Champix)
Record updated
5 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adults (≥18 years)
  • Current cigarette smokers (more than 5 cigarettes per day) who are interested in reducing or quitting in the next 6 months
  • Able to provide informed consent
  • Living in Ontario, Canada

Who cannot take part

  • Contraindications to any of the study medications (NRT, cytisine, varenicline)
  • Actively using one of the study medications in the past 7 days
  • Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French)
  • Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year)
  • Actively enrolled in another formal smoking cessation program
  • Pregnant or breastfeeding individuals

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this vanguard trial is to test whether clients of Sun Life are willing to join in a quit smoking program that offers counselling and tobacco cessation products to all participants over a 12-month period. The study team will track the safety and usage of 3 types of cessation products as well as the effectiveness of a virtual pharmacy (i.e. cessation products delivered to participants directly from a pharmacy). The goal is to recruit a minimum of 150 participants for this Vanguard phase.

Read full original descriptionShow less

The purpose of this study is to look at 3 approved smoking cessation products used in combination with counselling and virtual delivery of the smoking cessation products. The goal is to track product usage, safety, and adherence (how much of the products people use and how many counselling sessions they complete).

Within the study there will also be an observational group who will not receive study medication but who will receive free virtual coaching and follow-up for smoking cessation and complete study questionnaires.

The 3 groups in the trial

  • Nicotine Replacement Therapy (Nicotine patch plus NRT gum or lozenge)Existing treatment, for comparison

    Nicotine replacement therapy patch (titrated based on cigarettes consumed at baseline) plus short term gum or lozenge (as needed)

  • CytisineExisting treatment, for comparison

    Cytisine pills, standard dose

  • Varenicline (Champix)Existing treatment, for comparison

    Varenicline - standard dose

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation: A Randomized Controlled Trial
Record updated
5 March 2026